Mr. Swickard's investment supports

斯威卡德先生的投资支持

Araceli's work to replace animal testing with human cell science and grow Oregon's technology industry

阿拉塞利致力于用人體細胞科學取代動物實驗，並推動俄勒岡州科技產業的發展

PORTLAND, Ore.

俄勒冈州波特兰

,

，

Nov. 12, 2026

2026年11月12日

/PRNewswire/ -- Araceli Biosciences, a developer of high-performance cellular imaging platforms for drug discovery, today announced that Jeff Swickard has joined the investors backing the company's recently closed $4.5 million financing round, which is fueling record commercial momentum following two years of outsized growth, where Araceli's revenue is projected to grow six-fold in 2026 from the same period two years ago.

/美通社/ -- 高性能细胞成像平台开发商Araceli Biosciences今日宣布，Jeff Swickard已加入支持该公司最近完成的450万美元融资轮次的投资者行列。这笔资金正推动公司在经历两年的超常增长后，创下商业发展的新纪录。预计Araceli在2026年的收入将比两年前同期增长六倍。

Mr. Swickard is excited to support Araceli's work..

斯威卡德先生很兴奋能够支持阿拉塞利的工作。

Mr. Swickard's investment aligns with the broader shift Araceli has been enabling all year, as pharmaceutical companies move toward a tech-forward, AI-driven approach to drug discovery and adopt New Approach Methodologies (NAMs), modern methods that test whether a drug is safe and effective using human cell-based assays instead of animal models.

斯威卡德先生的投资契合了阿拉塞利全年以来所推动的更广泛转型，即制药公司正朝着以技术为先、人工智能驱动的药物研发方式迈进，并采用新替代方法（NAMs）——这是一种利用基于人类细胞的检测而非动物模型来测试药物安全性和有效性的现代方法。

Araceli's Endeavor® platform makes NAMs practical at scale, helping researchers monitor how human cells respond to a drug compound and generate faster, more accurate data earlier in development, with less reliance on animal testing..

Araceli 的 Endeavor® 平台使非动物方法（NAMs）能够大规模实用化，帮助研究人员监测人体细胞对药物化合物的反应，在开发早期生成更快速、更准确的数据，从而减少对动物实验的依赖。

Araceli's technology is trusted by leading pharmaceutical and life science companies, including 10 of the world's top 20 pharmaceutical companies, with a strong presence in the Bay Area, Boston, London, and Berlin.

Araceli 的技术受到领先制药和生命科学公司的信赖，其中包括全球前 20 强制药公司中的 10 家，并在湾区、波士顿、伦敦和柏林拥有强大的业务布局。

The investment also reflects Mr. Swickard's commitment to growing Oregon's technology and life sciences economy. Araceli, headquartered in Tigard, Oregon, is entering what it calls 'phase two' of its commercialization: launching consumable products optimized for its growing installed base, with a broader rollout planned for 2027..

此次投资也体现了斯威卡德先生对发展俄勒冈州科技和生命科学经济的承诺。总部位于俄勒冈州蒂加德的Araceli公司正进入其所谓的商业化“第二阶段”：推出为其不断增长的装机量优化的消耗品，并计划于2027年进行更广泛的推广。

'We're especially grateful to Jeff Swickard for his investment and for his commitment to making science more humane. His support reflects a belief that we share, which is that better science and more humane science go hand-in-hand. By helping researchers test potential drugs on human cell models earlier in development, our technology delivers faster, more accurate answers while reducing reliance on animal testing.

我们特别感谢杰夫·斯威卡德的投资，以及他致力于让科学研究更具人道精神的承诺。他的支持体现了一种与我们共有的信念，即更优质的科学与更具人道精神的科学是相辅相成的。通过帮助研究人员在药物开发的早期阶段利用人体细胞模型测试潜在药物，我们的技术能够提供更快速、更准确的结果，同时减少对动物实验的依赖。

Jeff's investment strengthens our ability to bring that approach to more labs, and we're proud to keep building it right here in Oregon,' said Shawn MacDonald, Araceli Biosciences Chief Financial Officer..

“杰夫的投资增强了我们将该方法推广至更多实验室的能力，我们很自豪能够在俄勒冈州持续推动其发展，”Araceli Biosciences 首席财务官肖恩·麦克唐纳表示。

'We are excited to join an impressive group of investors in Araceli Biosciences, an innovative Oregon company developing technology with the potential to modernize scientific research and reduce the need for animal testing. We believe the future of science should be smarter, faster, and more humane.

“我们很高兴能加入Araceli Biosciences的投资者行列，这是一家位于俄勒冈州的创新公司，正在开发有望使科学研究现代化并减少对动物实验需求的技术。我们相信，科学的未来应当更智能、更高效、更人道。”

That future is already taking shape in Oregon, and we're proud to be part of it,' said Jeff Swickard..

“这一未来在俄勒冈州已初具雏形，我们很自豪能参与其中。”杰夫·斯威卡德表示。

About Araceli Biosciences

关于Araceli Biosciences

Araceli Biosciences develops high-performance cellular imaging platforms designed to help researchers generate scalable, reproducible biological data for drug discovery and advanced screening applications. Founded in 2020 and spun out of Phoseon Technology in 2023, the company is headquartered in Tigard, Oregon, where most of its roughly 30 employees are based.

Araceli Biosciences 开发高性能细胞成像平台，旨在帮助研究人员生成可扩展、可重复的生物数据，用于药物发现和先进筛选应用。该公司成立于2020年，于2023年从 Phoseon Technology 分拆出来，总部位于俄勒冈州蒂加德，其约30名员工中的大多数在此办公。

Araceli's Endeavor® platform and AI-driven analysis software are used by pharmaceutical and biotechnology customers across North America and Europe. Learn more at aracelibio.com..

北美和欧洲的制药及生物技术客户正在使用 Araceli 的 Endeavor® 平台及其人工智能驱动的分析软件。更多信息请访问 aracelibio.com。

Forward-Looking Statements

前瞻性陈述

This release contains forward-looking statements, including expectations for 2026 revenue. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Araceli Biosciences undertakes no obligation to update these statements except as required by law..

本发布包含前瞻性陈述，包括对2026年收入的预期。这些陈述基于当前的预期和假设，并受可能导致实际结果出现重大差异的风险和不确定性的影响。Araceli Biosciences 除法律要求外，不承担更新这些陈述的义务。

Araceli Biosciences Investor and Media Contact:

Araceli Biosciences 投资者及媒体联系人：

[email protected]

[email protected]

SOURCE Araceli Biosciences

来源：Araceli Biosciences